# Xinchuan Biotechnology (Beijing) Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xinchuan-biotechnology-beijing-co

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Total disclosed funding: $16M
- Latest round: Seed (Mar 28, 2022)
- Investors on record: 3

## About

Based in Beijing, China, and founded in 2021, Xinchuan Biotechnology (Beijing) Co., Ltd operates as a developer of immune cell therapy drugs.

Based on its iPSC-CAR-NK immune cell therapy and organoid high-throughput screening technology, the company has arranged several CAR-NK product pipelines around cancers such as lung cancer, liver cancer, colorectal cancer and B-lymphoma.

## Funding rounds

- Seed, Mar 28, 2022, $16M — ChosenMed, Shenzhen Royal Capital, Zhejiang Yunrui Asset Management

## Investors

- ChosenMed — Seed
- Shenzhen Royal Capital (https://capitalatlas.ai/funds/shenzhen-royal-capital) — Seed
- Zhejiang Yunrui Asset Management — Seed